Daniel L. Alkon - 14 Jun 2021 Form 4 Insider Report for Synaptogenix, Inc. (SNPX)

Role: Chief Scientific Officer, Director
Signature: /s/ Robert Weinstein, Attorney-in-fact
Issuer symbol: SNPX
Transactions as of: 14 Jun 2021
Net transactions value: +$82,600
Form type: 4
Filing time: 16 Jun 2021, 13:01:35 UTC
Previous filing: 14 Jun 2021
Next filing: 01 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SNPX	Common Stock, par value $0.0001 per share	Purchase	$82,600	+10,000	+674%	$8.26^*	11,484	14 Jun 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.19 to $8.35, inclusive. The reporting person undertakes to provide to Synaptogenix, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.19 to $8.35, inclusive. The reporting person undertakes to provide to Synaptogenix, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney